Sath Shukla - 28 Aug 2023 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Signature
/s/ Tamara Joseph, Attorney-in-Fact for Sath Shukla
Issuer symbol
SPRO
Transactions as of
28 Aug 2023
Net transactions value
-$7,748
Form type
4
Filing time
30 Aug 2023, 16:20:21 UTC
Previous filing
03 Aug 2023
Next filing
05 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Sale $2,336 -1,854 -0.32% $1.26 576,663 28 Aug 2023 Direct F1
transaction SPRO Common Stock Sale $5,412 -4,163 -0.72% $1.30 572,500 29 Aug 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") that were granted to the Reporting Person on August 26, 2021 pursuant to a "sell to cover" provision included in the RSU Agreement.
F2 The reported transaction is a sale of common stock pursuant to a preexisting 10b5-1 plan upon the vesting of RSUs that were granted to the Reporting Person on August 26, 2021.